<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">

BIOTECH AND MONEY REBRANDS TO LSX TO REFLECT WIDER LIFE SCIENCE OFFERING

Biotech and Money is now LSX – The network for life science executive leaders

London, United Kingdom, 10/09/18 – Biotech and Money, the network for life science executive leaders, has become LSX - Life Science Executives. The rebranding reflects the evolution of the company and its vision for the future.

At its heart, our company is in the business of connecting senior life science executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses. Our name change from Biotech and Money to LSX reflects our ability to deliver these opportunities to the wider life sciences community.

We aim to build on our long-standing mission to forge a fundamentally better way to facilitate investment, foster partnerships, and build relationships in healthcare, while also better representing the community we serve and our role in helping life science executives tackle the challenges they face.

We do this through our world-class conferences and events that break the mould with innovative formats, networking and business development opportunities, as well as through powerful thought leadership and media offerings.

Terry O’Dwyer, Co-CEO, said: “We are exceptionally excited to be LSX. This rebrand presents a fantastic opportunity to build on our current offering and work with the life sciences community to better facilitate partnerships, deals and investment.”

Read More

OUR CONFERENCE AND COMMUNITY BRANDS

Biotech and Money Logo 2018 - Logo-1.png
Medtech and Money World Congress 2018-1.png
BM Investival Showcase
LSX Nordic Congress-1.png
LSX World Congress USA
LSX CEO Forum
LSX Connect
LSX Investor Club

INVESTMENT AND IPOS

Key challenges to scaling up early-stage investment in the life sciences

Access to venture capital and effective fundraising tactics are key to buil...

Read More

Playing the long game: preparation and persistence pay off

Securing external investment is an undisputed priority for senior managemen...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More
View More

M&A AND DEAL MAKING

Reviewing life sciences deal trends

For the first seven months of this year (to July) our Deal Watch analysis o...

Read More

Navigating M&A transactions in life sciences

An acquisition in the life sciences sector raises various issues, some of w...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More
View More

R&D TO COMMERCIALISATION

Commercialise and partner successfully in Europe and the Middle East

Understand how to commercialise via partnering in Europe and other markets ...

Read More

Examining AI's potential in healthcare

Artificial Intelligence (AI) systems hold great potential in taking on an i...

Read More

Enhancing your drug development journey

Experience drug development – designed around you®

Read More
View More

IP, REGULATION AND COMPLIANCE

Brexit: finite uncertainty

One might think that planning for uncertainty is something that biotech fir...

Read More

C-Suite challenges and how intellectual property can help meet them

The 2018 C-Suite Challenges in Life Sciences Survey from Biotech & Money/LS...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More
View More

TALENT AND EXECUTIVE STRATEGY

Bolstering women in the C-suite and boardroom

The leadership landscape within life sciences is beginning to change. More ...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More

The talent challenge in life sciences

A disconcerting 59% of investor respondents consider under one quarter of t...

Read More
View More

COMMUNITY PARTNERS

Alacrita
allen and overy
Appleyard Lees
barclays
Boult Wade Tennant
Cancer Research UK.jpg
capitalcell.png
CMS Cameron Mckenna.png
covington.png
eqs.png
gje.png
Gallagher.png
Horizon.png
Inceptua
Marks & Clerk Intellectual Property Services.jpeg
Xplico.png